grant
Clinical Core
Organization MAYO CLINIC ROCHESTERLocation ROCHESTER, UNITED STATESPosted 15 Sept 2019Deadline 31 Aug 2030
NIHUS FederalResearch GrantFY2025AD dementiaAD related dementiaADRDAccelerationAddressAffectAlzheimer Type DementiaAlzheimer disease dementiaAlzheimer sclerosisAlzheimer syndromeAlzheimer'sAlzheimer's DiseaseAlzheimer's and related dementiasAlzheimer's dementia and related dementiaAlzheimer's dementia or related dementiaAlzheimer's disease and related dementiaAlzheimer's disease and related disordersAlzheimer's disease or a related dementiaAlzheimer's disease or a related disorderAlzheimer's disease or related dementiaAlzheimer's disease related dementiaAlzheimers DementiaAutopsyBiological MarkersBlood PlasmaCOVID crisisCOVID epidemicCOVID pandemicCOVID-19 crisisCOVID-19 epidemicCOVID-19 eraCOVID-19 global health crisisCOVID-19 global pandemicCOVID-19 health crisisCOVID-19 pandemicCOVID-19 periodCOVID-19 public health crisisCOVID-19 yearsClinicalClinical DataClinical ResearchClinical SciencesClinical StudyClinical TrialsClinical Trials DesignClinical assessmentsCollectionCommunitiesComplexDNADataData CollectionData SetDeoxyribonucleic AcidDevelopmentDiagnosisDiseaseDisorderEnrollmentEpidemiologyEvaluationFDA approvedFTD dementiaFTLDFamily memberFosteringFrontal Temporal DementiaFrontal Temporal Lobar DegenerationFrontotemporal DementiaFrontotemporal Lobar DegenerationsFrontotemporal variety lobar degenerationFundingGeneticGoalsGrantHealth Care TechnologyHealth TechnologyImageIndividualInfrastructureInternationalInterventionInvestigatorsLaboratoriesMRI ScansMagnetic Resonance Imaging ScanMolecularMonitorNerve DegenerationNeuron DegenerationNeuropsychologiesNeuropsychologyNorth AmericaPBMCParticipantPeripheral Blood Mononuclear CellPersonsPhasePlasmaPlasma SerumPopulationPrevention trialPrimary Senile Degenerative DementiaProcessProductivityProtocolProtocols documentationQuality ControlRecommendationRegistriesResearchResearch PersonnelResearch PriorityResearch ResourcesResearchersResourcesReticuloendothelial System, Serum, PlasmaSARS-CoV-2 epidemicSARS-CoV-2 global health crisisSARS-CoV-2 global pandemicSARS-CoV-2 pandemicSARS-coronavirus-2 epidemicSARS-coronavirus-2 pandemicSamplingScanningSecureSevere Acute Respiratory Syndrome CoV 2 epidemicSevere Acute Respiratory Syndrome CoV 2 pandemicSevere acute respiratory syndrome coronavirus 2 epidemicSevere acute respiratory syndrome coronavirus 2 pandemicSiteStandardizationSymptomsSyndromeTechnology AssessmentUncertaintyUpdateVisitadvanced directivebio-markersbiologic markerbiomarkerclinical phenotypeclinical validationconferenceconventioncoronavirus disease 2019 crisiscoronavirus disease 2019 epidemiccoronavirus disease 2019 global health crisiscoronavirus disease 2019 global pandemiccoronavirus disease 2019 health crisiscoronavirus disease 2019 pandemiccoronavirus disease 2019 public health crisiscoronavirus disease crisiscoronavirus disease epidemiccoronavirus disease pandemiccoronavirus disease-19 global pandemiccoronavirus disease-19 pandemicdata sharingdepositorydesigndesigningdevelopmentaldigital healthdigital technologydoubtenrollepidemiologicepidemiologicalfront temporal dementiafrontal lobe dementiafrontotemporal lobar degeneration dementiafrontotemporal lobar dementiafrontotemporal lobe degeneration associated with dementiaimagingkindredmembernecropsyneural degenerationneural imagingneuro-imagingneurodegenerationneurodegenerativeneuroimagingneurological degenerationneurological imagingneuronal degenerationneuropsychologicnovelpatient stratificationphenotypic datapostmortempreventpreventingprimary degenerative dementiaprogramsrecruitremote assessmentremote evaluationrepositorysenile dementia of the Alzheimer typesevere acute respiratory syndrome coronavirus 2 global health crisissevere acute respiratory syndrome coronavirus 2 global pandemicstratified patientsummitsymposiasymposiumtreatment trialtrial planningvirtual technology
Description preview
Frontotemporal lobar degeneration (FTLD) represents the group of neurodegenerative proteinopathies that manifest as a spectrum of complex clinical syndromes. There are no FDA-approved interventions that positively affect symptoms, slow the rate of progression, or delay or prevent the development of symptoms for those who may develop FTLD. The…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click